NCT05758428已完成1 期
A Phase 1, Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Cmax of RPL554
研究概览
简要总结
This is a phase 1, open-label, parallel cohort study to evaluate the PK, safety and tolerability of nebulized ensifentrine following administration of single and multiple doses in healthy Chinese male subjects.
详细描述
This study consists of two cohorts, and approximately a total of up to 28 healthy male subjects, 14 subjects in Cohort 1, and 14 subjects in Cohort 2, will be enrolled. Cohort 2 will be randomly assigned to Sequence 1 and Sequence 2 according to the ratio of 1:1.
Treatment Group
- Cohort 1: subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID).
- Cohort 2: subjects will receive two single doses of 1.5 mg and 6 mg ensifentrine, separated by at least a 7-day washout period using crossover design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subjects (18-50 yrs) who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECG without abnormality or with abnormality of no clinical significance;
- •A male subject must agree to use contraception as detailed in the protocol from the screening visit to within 30 days of the last dose after study completion and refrain from donating sperm during this period;
- •Subjects never smoke or is ex-smoker for ≥ 12 months,never chewing tobacco within 90 days prior to screening;
- •Body weight must be ≥ 50 kg and body mass index (BMI) between 18.0 and 30.0 kg/m2.
排除标准
- •History or current malignancy of any organ system, treated or untreated within the past 5 years;
- •Known allergy, immune reaction, or intolerance to ensifentrine or any of the excipients of the formulation and/or ineligible to receive ensifentrine;
- •Subjects with the history of pulmonary and cardiovascular disease;
- •Any chronic condition or disease, including but not limited to: Metabolism, endocrine (such as diabetes, hypothyroidism/hyperthyroidism), liver, kidney, gastrointestinal tract, hematology or nervous system and other diseases;
- •Respiratory tract infection (upper and/or lower) treated with antibiotics within 12 weeks of screening visit;
- •Current infection of clinical significance or known ongoing inflammatory condition;
- •Live or attenuated vaccine(s) within 1 month prior to screening, or plan to receive such vaccines during the study;
- •Immunotherapy within 30 days of screening;
- •Subjects who participated in any other interventional clinical trials within 3 months prior to screening;
- •Subjects who have used any drugs that inhibit or induce liver metabolism of drugs within 30 days prior to screening or have used any drugs within 14 days prior to screening;
- •Subjects who have a history of alcohol or drug abuse, or have used any drug abuse within 6 months before screening;
- •Subjects with a positive alcohol breath test, or a positive urinalysis screening test or a positive smoke test;
- •Creatinine clearance < 80mL/min by Cockcroft-Gault formula;
- •Subjects who have clinically significant abnormalities in physical examination, vital signs, chest x-ray, and laboratory examinations;
- •Pulmonary function test: Subjects who have measured value of forced expiratory volume in first second (FEV1) / predicted value of FEV1 ≤ 80% or forced vital capacity (FVC) ≤ 80% of predicted value or any other clinically significant abnormality;
- •Subjects who have any of abnormal findings in 12-lead ECG or any other clinically significant abnormality;
- •Subjects who have undergone surgery within 6 months prior to the dosing of the study drug or who have undergone surgery within 4 weeks prior to the dosing of the study drug or who plan to undergo surgery during the trial;
- •Donated blood or blood products or had substantial loss of blood (more than 300 mL) within 56 days prior to the first administration of study treatment.
- •Unwilling to follow the lifestyle considerations;
- •Any other reason that the investigator considers the patient unsuitable to participate in the study.
研究组 & 干预措施
Cohort 1
Experimental
Subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID).
干预措施: Ensifentrine (Drug)
Cohort 2
Experimental
Subjects will receive two single doses of 1.5 mg and 6 mg ensifentrine, separated by at least a 7-day washout period using crossover design.
干预措施: Ensifentrine (Drug)
结局指标
主要结局
Cmax of RPL554
时间窗: 0 to 72 hours
Blood PK sampling for RPL554 concentration
t1/2 of RPL554
时间窗: 0 to 72 hours
Half-life of RPL554
Tmax of RPL554
时间窗: 0 to 72 hours
Time to maximum observed plasma concentration
AUC0-t of RPL554
时间窗: 0 to 72 hours
Area under the plasma concentration from time 0 to the last collection time after drug administration
次要结局
- Adverse events(From the first dose usage to the end of the study, approxiamtely up to 15 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Japanese Pharmacokinetic Bridging Study for CC-93538Healthy VolunteersNCT04096105Celgene48
已完成
1 期
Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult SubjectsHealthy VolunteersNCT04373187Celgene52
招募中
1 期
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCMalignant Pleural EffusionsNSCLC Stage IVNCT05543330Wuhan YZY Biopharma Co., Ltd.116
已完成
1 期
A Study of Subcutaneous KY1005 in Healthy VolunteersImmune System DiseasesNCT04449939Kymab Limited24
已完成
1 期
A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese ParticipantsHealthy VolunteersNCT03276052AstraZeneca20